In a major breakthrough, pharmaceutical giants Pfizer and BioNTech have announced “positive” results from initial trials of their combined mRNA vaccine against both COVID-19 and influenza. The phase one and two trials demonstrated “robust immune responses” against both illnesses and a safety profile consistent with the companies’ COVID-19 vaccine. Combination vaccines, like the Pfizer-BioNTech mRNA vaccine, have the potential to become a routine vaccination against respiratory diseases. BioNTech’s COVID-19 vaccine, for example, was developed and approved in less than a year. For example, BioNTech’s COVID-19 vaccine was developed and approved in less than a year, showcasing the efficiency of this innovative approach.

Source: Economic Times October 27, 2023 06:45 UTC